venlafaxine / Generic mfg. - LARVOL DELTA

Chronopharmacology and implications for the safety and efficacy of anticonvulsants, antipsychotics, and antidepressants: A systematic review. (PubMed, J Psychopharmacol) - "Current evidence provides preliminary support that circadian rhythm may differentially affect the pharmacology of select psychotropic agents. Whether the foregoing translates into clinically meaningful differences in efficacy, tolerability, and/or posology of the evaluated agents/classes requires systematic evaluation. Given that evidence is predominantly preclinical, further studies using clinically relevant repeated-dose regimens and disease-relevant animal models are required."

Journal • Review • CNS Disorders • Epilepsy

Missed Opportunity for Gut-Brain Neuromodulators in Adults With Inflammatory Bowel Diseases? (ACG 2026) - "Adults with IBS (n=1,328,386), compared to IBD (n=677,726) or the reference non-IBD/IBS cohort (n=88,411,163), were more likely to be female (76%, 55%, and 54%) ( Table 1 ). Anxiety and depression were more common in patients with IBD (31%, 28%) and IBS (56%, 45%) than in the nonâIBD/IBS population (12%, 10%) (all SMD >0.45; all p< .0001) ( Table 1 ). Neuromodulators were less commonly prescribed in patients with IBD than in those with IBS (aOR 0.85, 95% CI 0.84-0.85), but more commonly than in the general population (aOR 1.28, 95% CI 1.27-1.30)."

Clinical • CNS Disorders • Depression • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mood Disorders

When Constipation Becomes a Renal Emergency: Stercoral Proctocolitis With Fecaloma-Induced Bilateral Hydroureteronephrosis and Obstructive Acute Kidney Injury (ACG 2026) - "Her medications included hydroxyzine, carbamazepine, mirtazapine, primidone, pregabalin, deutetrabenazine, and venlafaxine, contributing to a high anticholinergic burden. Massive fecal impaction causing stercoral proctocolitis and obstructive uropathy. Figure Footnote: The distended colon compresses the distal ureters resulting in bilateral hydroureteronephrosis (arrows)."

Acute Kidney Injury • Bipolar Disorder • Cardiovascular • CNS Disorders • Constipation • Endocrine Disorders • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hypotension • Infectious Disease • Inflammatory Bowel Disease • Movement Disorders • Nephrology • Parkinson's Disease • Renal Disease

QTc changes and early major adverse cardiovascular events associated with antidepressant treatment for major depressive disorder in adults: individual participant data network meta-regression of double blind randomised trials. (PubMed, BMJ) - "The effect of specific antidepressants on QTc interval differed between adults with depression. No evidence associated antidepressant use with early MACE and non-suicidal sudden death. To support shared decision making and taking into account the trade-off between benefits and harms, individual modifiable and non-modifiable risk factors should be considered when choosing antidepressants."

Adverse events • Clinical • Journal • Cardiovascular • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Venlafaxine for the Prevention of Postherpetic Neuralgia in Patients with Acute Herpes Zoster: Protocol for a Randomized Controlled Trial. (PubMed, J Pain Res) - P=N/A | "ClinicalTrials.gov identifier: NCT07361796. Registered on January 2026 (https://clinicaltrials.gov/study/NCT07361796?term=NCT07361796)."

Journal • Herpes Zoster • Neuralgia • Pain • Varicella Zoster

Drugs for prevention of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Comparison table: Some drugs for migraine prevention. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

VENLAFAXINE-INDUCED ACUTE EOSINOPHILIC PNEUMONIA: A CASE REPORT AND LITERATURE REVIEW (CHEST 2026) - No abstract available

Case report • Clinical • Review • Infectious Disease • Pneumonia • Respiratory Diseases

Real-World Effectiveness and Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: A Retrospective Observational Study. (PubMed, Healthcare (Basel)) - "Background/Objectives: This study evaluated the real-world effectiveness and safety of intranasal esketamine plus oral antidepressants compared with venlafaxine-based oral antidepressant therapy in adults with moderate-to-severe treatment-resistant depression (TRD). In this retrospective routine care cohort, esketamine was used in patients with more complex TRD and was associated with modestly lower matched follow-up PHQ-9 scores. The observational design, baseline imbalance, and attrition precluded causal conclusions."

Journal • Observational data • Real-world evidence • Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Sexual Disorders

Therapeutic Drug Monitoring-Guided Management of Venlafaxine Overdose in an Adolescent: a case report. (PubMed, J Anal Toxicol) - "The apparent elimination half-life was prolonged to 14.4 hours for venlafaxine and 17.7 hours for ODV. Genotyping revealed the COMT rs4680 Met/Met genotype, which may theoretically influence catecholamine metabolism; however, its contribution to the clinical presentation remains uncertain."

Journal • Cardiovascular • CNS Disorders • Epilepsy • Ophthalmology • COMT • MB

Evodiamine alleviates CUMS-induced depressive-like behaviors associated with modulation of uptake-2 transporters. (PubMed, Xenobiotica) - "Male C57BL/6J mice were subjected to CUMS and orally administered evodiamine (20 or 40 mg/kg/day) or venlafaxine (20 mg/kg/day) once daily for 8 weeks, while tissue levels of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) in the prefrontal cortex (PFC) were quantified...Furthermore, evodiamine potently inhibited OCT2-, OCT3-, and PMAT-mediated uptake of monoamine neurotransmitters, with the strongest inhibitory activity observed toward hOCT3-mediated transport.4. These findings suggest that the antidepressant-like effects of evodiamine are associated with enhanced monoaminergic neurotransmission through inhibition of uptake-2 transporters, highlighting its potential as a novel therapeutic candidate for depression."

Journal • CNS Disorders • Depression • Psychiatry

Case Report: Complex venlafaxine overdose and prolonged intensive care unit hospitalization associated to combined CYP2D6 and CYP2C19 polymorphisms. (PubMed, Front Psychiatry) - "This case underscores the importance of early plasma monitoring and pharmacogenetic assessment in overdose management, as a rare metabolic profile affecting VEN clearance contributed to prolonged toxicity and complex ICU management. To our knowledge, this is one of the first cases to describe the potential clinical impact of a rare combined CYP2D6/CYP2C19 polymorphism."

Journal • Cardiovascular • CNS Disorders • Critical care • Epilepsy • Hypoglycemia • CYP2C19

Acute catatonia and psychosis in the context of seizure exacerbation in epilepsy: a case report. (PubMed, Front Psychiatry) - "We report a 44-year-old woman with a 27-year history of epilepsy, maintained on carbamazepine and topiramate, and a longstanding psychiatric history of major depressive disorder, obsessive-compulsive symptoms, and chronic nihilistic delusions and intermittent hallucinations documented at baseline. One week before admission, her antidepressant was switched from clomipramine to venlafaxine 150 mg/day...Management with escalating benzodiazepines and cautious antipsychotic uptitration (quetiapine XR, cariprazine) was associated with complete catatonic remission and psychotic symptom resolution over 29 days...Clinicians should resist anchoring on temporal associations between seizure activity and psychiatric symptoms. EEG findings must be interpreted in their pharmacological context; pharmacokinetic interactions should inform antipsychotic dose selection; and QTc prolongation warrants structured cardiac monitoring."

Journal • Anesthesia • CNS Disorders • Depression • Epilepsy • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry • CYP3A4

Association between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure: a retrospective study on two cohorts from Norway and the UK. (PubMed, Lancet Psychiatry) - "CYP2D6 PM status was consistently associated with increased risk of venlafaxine treatment failure in two large, real-life cohorts, suggesting that pre-emptive genotyping could facilitate personalised venlafaxine therapy."

Journal • Observational data • Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Psychiatry • CYP2C19

CYP2D6, CYP2C19, and venlafaxine: from plasma concentration to clinical decision. (PubMed, Lancet Psychiatry) - No abstract available

Journal • CYP2C19

Association Between CYP450 Polymorphisms and Treatment Outcomes of Escitalopram and Venlafaxine in Patients with Post Stroke Depression. (PubMed, Neuropsychiatr Dis Treat) - "These findings underscore the need for further exploration into the clinical utility of pharmacogenetics. Future antidepressant treatment should prioritize cost-effective, pragmatic approaches over costly genetic testing alone."

Journal • Cardiovascular • CNS Disorders • Depression • Mood Disorders • Psychiatry • CYP2C19 • CYP2D6

Effectiveness and Safety of Venlafaxine in Japanese Major Depressive Disorder Patients with or without Anxious Distress (EXPAND Study): A 12-Week Prospective Observational Study. (PubMed, Neuropsychiatr Dis Treat) - "These results provide descriptive real-world evidence on treatment outcomes; however, they should be interpreted with caution given the non-comparative study design and other limitations. The findings may inform clinical decision-making in patients with heterogeneous presentations encountered in routine psychiatric practice."

Journal • Observational data • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry

Venlafaxine shortage: commonly used antidepressant out of stock in UK until November. (PubMed, BMJ) - No abstract available

Journal

Drug-induced stuttering following serotonin reuptake inhibitors treatment: About two case reports and literature review. (PubMed, Encephale) - No abstract available

Journal

Serotonin Norepinephrine Reuptake Inhibitors and the Risk of Serious Adverse Events (clinicaltrials.gov) - P=N/A | N=8688 | Active, not recruiting | Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2027

Adverse events • Enrollment closed • Serious adverse event • Trial completion date • Chronic Kidney Disease • Nephrology • Renal Disease

TNA-LBP: Treating Negative Affect in Low Back Pain Patients (clinicaltrials.gov) - P2 | N=308 | Completed | Sponsor: Ajay Wasan, MD, Msc | Phase classification: P2/3 ➔ P2

Phase classification • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Patient characteristics, treatment patterns and clinical response in patients with treatment resistant depression starting a new treatment in the clinical setting: a multicenter, observational study in Portugal. (PubMed, Front Psychiatry) - "TRD treatments initiated at baseline were varied; the most common treatments initiated or ongoing at baseline were mirtazapine (43.1%), venlafaxine (42.5%), quetiapine (25.5%), and trazodone (20.9%). Outcomes for patients with TRD in real-world clinical practice remain poor, with most patients not responding after 20 weeks of treatment. Treatment heterogeneity highlights a lack of clinical consensus, and the need for novel therapeutics and improved treatment protocols for TRD in real-world clinical practice in Portugal."

Clinical • Journal • Observational data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Psychopharmacological Mechanisms of Antidepressant Withdrawal: Insights From Venlafaxine. (PubMed, Hum Psychopharmacol) - "Recognizing ADS as an intrinsic, predictable phase of chronic antidepressant pharmacotherapy-not an incidental complication or adverse effect-should guide informed consent, tapering practices, and future drug development. This narrative review examines ADS through pharmacological and neurobiological frameworks, using VEN to illustrate candidate mechanisms, clinical features, and risks."

Journal • Review • CNS Disorders • Psychiatry

High-Dose Vitamin D3 and Resveratrol as an Augmentation Strategy for Persistent Depressive Symptoms in Medicated Patients with Major Depressive Disorder and Comorbid Hypothyroidism (WFSBP 2026) - "The addition of high-dose vitamin D3 and trans-resveratrol to antidepressant (venlafaxine or escitalopram) and levothyroxine therapy for 12 weeks is a highly effective, safe, augmentation strategy for patients with MDD and comorbid hypothyroidism suffering from persistent depressive symptoms."

Clinical • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • IL6 • TNFA

CYP2D6 Allele and Metabolizer Phenotype Distribution in a Central Indian Depression Cohort: Interim Pharmacogenetic Findings (WFSBP 2026) - "These findings have direct implications for antidepressant prescribing. CYP2D6 PMs may experience higher exposure and adverse effects with paroxetine, fluvoxamine, venlafaxine, TCAs, and vortioxetine, while UMs risk subtherapeutic response. The substantial IM proportion may have altered dose requirements."

Biomarker • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • CYP2D6